Biochemical markers and the FDA Critical Path: How biomarkers may contribute to the understanding of pathophysiology and provide unique and necessary tools for drug development

Author: Karsdal M. A.   Henriksen K.   Leeming D. J.   Mitchell P.   Duffin K.   Barascuk N.   Klickstein L.   Aggarwal P.   Nemirovskiy O.   Byrjalsen I.   Qvist P.   Bay-Jensen A. C.   Dam E. B.   Madsen S. H.   Christiansen C.  

Publisher: Informa Healthcare

ISSN: 1366-5804

Source: Biomarkers, Vol.14, Iss.3, 2009-05, pp. : 181-202

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract